摘要：Those committed to the free exchange of scientific information have long complained about various restrictions on access to the FDA's pharmaceutical data and the resultant restrictions on open discourse. A review of open-government procedures and litigation at the FDA demonstrates that the need for transparency at the agency extend well beyond the reach of any clinical trial registry.
关键词：FDA approval; Public access; Pharmaceuticals; Accountability; Disclosure; Freedom of information; Drug approval; Clinical trials
